The short version of MOD GRF 1-29 fits in a sentence. The long version — which is the one that helps — is below.
Reviewed 2025-11-16. Anything still debated is marked as such rather than presented as settled.
Once in circulation, the peptide binds the growth hormone-releasing hormone receptor displayed on pituitary somatotroph cells. Receptor activation couples to Gs proteins, elevates intracellular cyclic AMP, and drives protein kinase A signaling inside the cell. That cascade increases discharge of growth hormone into the bloodstream. The analog therefore operates through a receptor pathway that already exists for the body's own releasing hormone, rather than through an engineered artificial target.
Clearance profiles diverge sharply between the two versions. The albumin-binding molecule stays in plasma for several days, whereas the unmodified analog is largely gone within about half an hour in reported work. Cleavage by dipeptidyl peptidase IV is a major contributor to the short life of the unmodified sequence. These gaps mean the two versions cannot be substituted for each other in study design or in reading results side by side.
Lyophilized peptide powder is comparatively stable when kept dry, cold, and protected from light. Once dissolved, the molecule is vulnerable to deamidation, oxidation, and aggregation, with the rate depending on pH, buffer composition, and temperature. Alkaline conditions and repeated freeze-thaw cycles accelerate loss of the intact peptide. The methionine present in the native sequence is a known oxidation site, which is one reason it was replaced in the modified fragment. Suppliers typically recommend cold storage of solutions and use within a short window.
Analytical confirmation usually relies on reversed-phase high-performance liquid chromatography for purity and on liquid chromatography coupled to mass spectrometry for identity. Mass data reveal the expected molecular mass and can flag truncated or oxidized species. Amino acid analysis and peptide mapping provide sequence-level verification. Immunoassays are used in some biological matrices, but antibodies raised against one releasing-hormone analog may cross-react with another. Reported purity figures depend heavily on the method used, so comparisons between suppliers require matching the analytical approach.
The two variants differ dramatically in how long they persist in circulation. The form lacking the albumin-binding group has a plasma half-life measured in tens of minutes, comparable to the natural hormone fragment. The version carrying the drug affinity complex binds albumin and shows a half-life of roughly six to eight days in human studies. That figure comes from small trials that tracked hormone levels over extended periods. The physiological consequences of sustained versus pulsatile stimulation are still debated and the literature does not settle the point.
| Property | Value | Notes |
|---|---|---|
| Primary target | GHRH receptor | Present on pituitary somatotroph cells |
| Signal pathway | Gs, cyclic AMP, protein kinase A | Sequence follows receptor activation |
| Main measured effect | Growth hormone release | Insulin-like growth factor 1 shifts indirectly |
| Half-life, binding form | Several days | Extended through serum albumin association |
| Half-life, unmodified form | About 30 minutes | Limited mainly by enzymatic cleavage |
Studies in this area generally track growth hormone pulses, insulin-like growth factor 1 concentrations, and occasionally body composition endpoints. Most published human data come from early, small trials, and questions about long-term effects remain open. Whether repeated exposure alters pituitary responsiveness over time is not settled. Analytical work relies on immunoassays for the hormones and on mass spectrometry for the peptide itself, because the two measurements answer different questions.
Binding of the peptide to the growth hormone-releasing hormone receptor on pituitary somatotrophs triggers a G protein coupled cascade that raises cyclic AMP and opens calcium channels. The result is greater secretion of growth hormone into the bloodstream. Because the peptide acts at the same receptor as the natural hypothalamic hormone, its effect is amplified pulse size rather than an entirely separate release pathway. Receptor binding alone does not determine the response, since somatostatin tone and other inputs modulate the final output.
The albumin-binding version stays in circulation for days, because covalent attachment to serum albumin shields the peptide from rapid filtration and degradation. Reported half-lives for this form fall in the range of several days. The version without the linker is cleared in minutes, with estimates often near thirty minutes in animal work. These figures come from small studies and vary with assay method, species, and route, so they are best read as approximate rather than fixed constants.
Four amino acid substitutions separate the modified backbone from the parent GRF(1-29) sequence. These changes reduce recognition by dipeptidyl peptidase IV and related proteases, extending the interval before degradation. Development work in this area sought longer-acting GHRH analogs for endocrine investigation. Published descriptions treat the substitution set as a defining property of the core sequence, while the albumin-binding linker is described separately as an optional addition to that same backbone.
CJC-1295 is a synthetic peptide analog of growth hormone-releasing hormone, constructed on the 29-amino-acid fragment designated GRF(1-29). The name began as an internal development code during the 1990s and later spread through research supply catalogs and discussion forums. The molecule does not occur in nature; its sequence is engineered rather than isolated from tissue. Two related compounds are sold under this single label, and they differ by one appended chemical group that strongly influences how long the peptide remains in circulation.
The second form adds a maleimide-bearing linker to the lysine at the carboxyl end. This group reacts with cysteine-34 on circulating serum albumin, forming a covalent bond that keeps the peptide in the bloodstream for far longer. ConjuChem developed the molecule as a way to extend the action of a peptide without frequent administration. The albumin attachment is the defining structural feature of the drug affinity complex version. Whether continuous exposure produces effects distinct from shorter pulses remains an unresolved research question.
CJC-1295 belongs to a family of synthetic peptides modeled on growth hormone-releasing hormone, the hypothalamic signal that prompts the pituitary to release growth hormone. The compound is built from the first twenty-nine amino acids of the natural human sequence, a fragment that retains full receptor binding capacity. Native growth hormone-releasing hormone is degraded quickly in circulation, so the fragment alone has limited practical value. Early work therefore focused on chemical modifications that preserve receptor binding while slowing enzymatic breakdown. The result is a molecule described in the literature as a long-acting analog of the natural hormone.
The core sequence keeps the receptor-binding region of GHRH while replacing four positions that are vulnerable to dipeptidyl peptidase-4 and other proteases. Substitutions at positions 2, 8, 15, and 27 raise metabolic stability relative to the natural hormone. The N-terminal residues remain essential for activity, so changes there generally lower potency. Molecular weight sits near 3368 daltons for the tetrasubstituted analog without the linker, while the albumin-binding form is heavier because of the added maleimide group.
CJC-1295 is a synthetic peptide modeled on growth hormone-releasing hormone, the hypothalamic signal that prompts the pituitary to release growth hormone. Its sequence corresponds to the first twenty-nine residues of human GHRH, with four substitutions that slow enzymatic breakdown. Early descriptions placed the compound in research on growth hormone deficiency and related conditions, and later literature groups it with the long-acting GHRH analogs. The name appears in both laboratory and popular fitness writing, where it sometimes labels chemically different peptides.
Chip-on-board arrays Surface-mounted LEDs are frequently produced in chip on board (COB) arrays, allowing better heat dissipation than with a single LED of comparable luminous output. The LEDs can be arranged around a cylinder, and are called "corn cob lights" because of the rows of yellow LEDs.
=== 29 July === Russian forces took the villages of Novoselivka Persha, 20 kilometers northwest of Avdiivka, and Vovche in Donetsk Oblast. The Russian defence ministry claimed to have intercepted 39 Ukrainian drones over five oblasts. Local media and officials claimed power failures along the western border due to damage caused by drone strikes. A fire occurred at an electrical substation in Tomarovka, Belgorod Oblast, and a power station in Glazunovka, Oryol Oblast was reported damaged, while falling debris damaged a “critical infrastructure facility” in Ostrogozhsky, Voronezh Oblast. Ukrainian authorities announced the arrest of six people in Odesa on suspicion of burning 15 military vehicles on behalf of Russia.
JEOL, Ltd. (日本電子, Nihon Denshi Kabushiki-kaisha; Nihon meaning Japan and Denshi meaning electron) is a major developer and manufacturer of electron microscopes and other scientific instruments, industrial equipment and medical equipment. Its headquarters are in Tokyo, Japan, with 25 domestic and foreign subsidiaries and associated companies as of 2014. It is listed in the top ten businesses worldwide for analytical laboratory instrument manufacturing. It has been included in the Activest Lux Nanotech Mutual Fund and the WestLB Nanotech Fund.
=== Fleischmann–Pons experiment === The most famous cold fusion claims were made by Stanley Pons and Martin Fleischmann in 1989. After a brief period of interest by the wider scientific community, their reports were called into question by nuclear physicists. Pons and Fleischmann never retracted their claims, but moved their research program from the US to France after the controversy erupted.
Sources: en.wikipedia.org
Under its terms the Basuto would be allowed to keep their guns, provided they officially register them and pay an annual fee of one pound per weapon. The Cape pledged to provide an amnesty for the rebels and allow for Quthing to remain a part of Basutoland. The Basuto agreed to pay a collective fine of 5,000 cattle and compensate Basuto loyalists and white traders. The Award marked the end of the conflict. The Cape's casualties during the war totaled 94 killed and 112 wounded.
selfish genetic element Also selfish DNA or parasitic DNA. Any genetic material (e.g. a gene or any other DNA sequence) which can enhance its own replication and/or transmission into subsequent generations at the expense of other genes in the genome, even if doing so has no positive effect or even a net negative effect on the fitness of the genome as a whole. Selfish elements usually work by producing self-acting gene products which repeatedly copy and paste their own coding sequences into other parts of the genome, independently of normal DNA replication (as with transposable elements); by facilitating the uneven swapping of chromosome segments during genetic recombination events (as with unequal crossing over); or by disrupting the normally equal redistribution of replicated material during mitosis or meiosis such that the probability that the selfish element is present in a given daughter cell is greater than the normal 50 percent (as with gene drives).
DWNT synthesis on the gram-scale by the CCVD technique was first proposed in 2003 from the selective reduction of oxide solutions in methane and hydrogen. The telescopic motion ability of inner shells, allowing them to act as low-friction, low-wear nanobearings and nanosprings, may make them a desirable material in nanoelectromechanical systems (NEMS) . The retraction force that occurs to telescopic motion is caused by the Lennard-Jones interaction between shells, and its value is about 1.5 nN.
== M == M13 phage - m7G(5')pppN diphosphatase - malformation - maltose-transporting ATPase - manganese-transporting ATPase - mannose-6-phosphate 6-reductase - mapping - marker - melanoma - melting - menaquinol oxidase (H+-transporting) - Johann Mendel - Mendelian inheritance - message - messenger RNA - metaphase - methylphenyltetrahydropyridine N-monooxygenase - methylsterol monooxygenase - methyltetrahydroprotoberberine 14-monooxygenase - microarray technology - microsatellite - MIMT1 - minusheet perfusion culture system - Mir-188 microRNA precursor family - Mir-615 microRNA precursor family - Mir-675 microRNA precursor family - missense mutation - mitochondrial DNA - mobility shift - molecular weight size marker - monoclonal antibody - monosaccharide-transporting ATPase - monosomy - morphine 6-dehydrogenase - mouse model - mRNA - multicistronic message - multicopy plasmid - multiple cloning site - multiple endocrine neoplasia, type 1 - mutation - myristoyl-CoA 11-(E) desaturase - myristoyl-CoA 11-(Z) desaturase -
Next come the 4p orbitals, completing the row, which are filled progressively by gallium ([Ar] 3d10 4s2 4p1) through krypton ([Ar] 3d10 4s2 4p6), in a manner analogous to the previous p-block elements. From gallium onwards, the 3d orbitals form part of the electronic core, and no longer participate in chemistry. The s- and p-block elements, which fill their outer shells, are called main-group elements; the d-block elements (coloured blue below), which fill an inner shell, are called transition elements (or transition metals, since they are all metals). The next 18 elements fill the 5s orbitals (rubidium and strontium), then 4d (yttrium through cadmium, again with a few anomalies along the way), and then 5p (indium through xenon). Again, from indium onward the 4d orbitals are in the core. Hence the fifth row has the same structure as the fourth.
Sources: en.wikipedia.org
It acts on the growth hormone-releasing hormone receptor found on pituitary somatotroph cells. Activation of that receptor triggers growth hormone release through a cyclic AMP dependent pathway.
It links the peptide to serum albumin after administration, which delays removal from circulation. Reported half-life shifts from roughly half an hour to several days as a result.
Most published work tracks serum growth hormone and insulin-like growth factor 1 over time. Sampling schedules and assay methods vary enough that figures are not directly comparable across reports.
The version carrying the affinity complex bears a maleimide group that binds serum albumin, which extends its circulation time to several days. The version without it lacks this group and clears within roughly half an hour. The two are chemically related but behave very differently once in the body.